Skip to Main Content

Paper Details

CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR) in Naive/Memory T Cells for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma.
Cancer Discov
20
2023
Author NameAffiliation
John T SchillerDavid Geffen School of Medicine at University of California, Los Angeles (university of california los angeles)
John T SchillerJonsson Comprehensive Cancer Center, David Geffen School of Medicine at university of california los angeles
Antoni RibasDavid Geffen School of Medicine at University of California, Los Angeles (university of california los angeles)
Antoni RibasJonsson Comprehensive Cancer Center, David Geffen School of Medicine at university of california los angeles
Antoni RibasParker Institute for Cancer Immunotherapy Center at university of california los angeles
Antoni RibasDavid Geffen School of Medicine at university of california los angeles
Antoni RibasDavid Geffen School of Medicine at university of california los angeles
Antoni RibasDavid Geffen School of Medicine at University of California, Los Angeles (university of california los angeles)
Antoni RibasJonsson Comprehensive Cancer Center, David Geffen School of Medicine at university of california los angeles
Antoni RibasParker Institute for Cancer Immunotherapy Center at university of california los angeles
Antoni RibasDavid Geffen School of Medicine at university of california los angeles
Antoni RibasDavid Geffen School of Medicine at university of california los angeles
  • 1 - 12

Datasets